Prognostický význam amplifikace 1q21 u pacientů s mnohočetným myelomem léčených bortezomibem (Velcade), thalidomidem (Myrin) a konvenční chemoterapií

Warning

This publication doesn't include Faculty of Arts. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Title in English	Prognostic impact of chromosome 1q21 amplification in patients with multiple myeloma treated by bortezomib (Velcade), thalidomide (Myrin) and any conventional therapy
Authors	NĚMEC Pavel GREŠLIKOVÁ Henrieta ZAORALOVÁ Romana FILKOVÁ Hana VRANOVÁ Vladimíra KUPSKÁ Renata SMEJKALOVÁ Jana OLTOVÁ Alexandra KUGLÍK Petr ADAM Zdeněk KREJČÍ Marta POUR Luděk HÁJEK Roman
Year of publication	2007
Type	Conference abstract
MU Faculty or unit	Faculty of Medicine
Citation
Description	This study is aimed at comparison of prognostic impact of 1q21 amplification in multiple myeloma patients treated by Veldace, Myrin and conventional therapy. Patients treated with thalidomide based ragimen seem to have trend towards worse prognosis based on overall survival.
Related projects:	Molecular basis of cell and tissue regulations University Research Centre - Czech Myeloma Group